NEW YORK (GenomeWeb News) – Myriad Genetics and Janssen Research & Development today announced they will use Myriad's BRACAnalysis test in a Phase III clinical trial for Yondelis (trabectedin).

Janssen is developing Yondelis as a treatment for advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancers. The firm is studying the drug in combination with a chemo regimen in the third-line setting comparing it against just chemotherapy in patients who have had two previous lines of platinum-based chemo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.